Brief: Hofseth Biocare Q2 Gross Oper Rev Up At NOK 80.4 Mln
Aug 23 (Reuters) - Hofseth Biocare ASA HBC.OL :
* GROSS OPERATING REVENUES OF NOK 80.4M (76.4M) IN Q2
* GROSS MARGIN IN Q2 WAS 34 PERCENT, WHICH IS LOWER THAN Q1
* IS STILL TARGETING C. 50 % GROWTH IN SALES, A HIGHER CAPACITY UTILIZATION AND POSITIVE
EBITDA AT
END OF YEAR
Source text for Eikon: ID:nGNE68nqXk
Further company coverage: HBC.OL
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Hofseth Biocare ASA
See all newsBrief: HBC Publishes Clinical Trial, Calls It Paradigm-Changing
Brief: Hofseth Biocare Says Demand Outlook For 2026 Is Improving Rapidly
Norway's Hofseth Biocare Q4 revenue rises on Human Nutrition demand
Brief: Hofseth BioCare To Cancel Subsequent Offering
Brief: Hofseth Biocare Announces Results Of Subsequent Offering